This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Small-Cap Winners & Losers

NeurogesX (NGSX) was one of the biggest winners in Tuesday's cheery small-cap session as the biopharmaceutical company surged nearly 21% on positive top-line clinical trial results.

The San Carlos, Calif., company said the late-phase study -- which tested its NGX-4010 pain relief patch for patients with postherpetic neuralgia (a complication of shingles) -- achieved the primary and all secondary endpoints . Shares of NeurogesX were up $1.49 to $8.60.

Elsewhere in the health care sector, Massachusetts-based GTC Biotherapeutics (GTCB) climbed 12.8% after the Food and Drug Administration granted fast track designation to the company's ATryn compound. ATryn is proposed to treat hereditary antithrombin deficiency patients at risk for developing thrombosis or thromboembolism (respectively, blood clots in deeply embedded veins or blood clot lodgment) during surgery or childbirth.

GTC can now also submit the associated Biologics License Application for ATryn on a rolling basis. Shares were trading at $1.17, up 15 cents.

Semiconductor-equipment maker Kulicke & Soffa Industries (KLIC - Get Report), based in Fort Washington, Pa., boosted its fourth-quarter sales forecast by $14 million to roughly $226 million. That should top the average analyst forecast by $13 million, according to Thomson Financial. Shares ratcheted up 9.1% to $9.33.

Elsewhere, clean-energies company Hoku Scientific (HOKU) soared 17% to $10.71 after Piper Jaffray upped the stock rating to market perform from underperform.

In the red, however, were several names pressured by negative analyst calls.

PeopleSupport (PSPT), for instance, fell 7.9% after JMP Securities cut the outsourcer to market perform from market outperform, citing the threat that the Los Angeles-based outfit might lose contracts with Washington Mutual and EarthLink -- two of its biggest clients. Shares were down 99 cents at $11.59.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
NGSX $0.01 0.00%
HSII $25.46 0.00%
KLIC $13.19 0.00%
AAPL $132.54 0.00%
FB $80.54 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs